Ligand Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Ligand Pharmaceuticals şirketinin kazançları yıllık ortalama -47.7% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 1.2% oranında artan oldu. Gelirler yıllık ortalama 0.2% oranında azalan oldu. Ligand Pharmaceuticals şirketinin öz sermaye getirisi 5.4% olup, net marjı 29.7% dir.

Anahtar bilgiler

-47.7%

Kazanç büyüme oranı

-43.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	6.0%
Gelir büyüme oranı	-0.2%
Özkaynak getirisi	5.4%
Net Marj	29.7%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Oct 31

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 18

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Jun 29

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

May 23

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27

Ligand Pharmaceuticals: Moving Parts Keep Moving

Mar 29

Gelir ve Gider Dağılımı

Ligand Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGM:LGND Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	152	45	69
30 Jun 24	133	42	59
31 Mar 24	118	96	53
31 Dec 23	131	54	53
30 Sep 23	154	21	68
30 Jun 23	180	41	68
31 Mar 23	204	51	69
31 Dec 22	196	-5	70
30 Sep 22	183	23	46
30 Jun 22	188	27	44
31 Mar 22	223	45	46
31 Dec 21	242	76	47
30 Sep 21	275	68	49
30 Jun 21	252	48	51
31 Mar 21	208	39	47
31 Dec 20	164	7	39
30 Sep 20	143	-16	45
30 Jun 20	126	-25	39
31 Mar 20	110	-61	40
31 Dec 19	120	629	42
30 Sep 19	153	594	43
30 Jun 19	174	677	43
31 Mar 19	239	764	41
31 Dec 18	251	143	38
30 Sep 18	242	179	34
30 Jun 18	230	120	32
31 Mar 18	168	53	29
31 Dec 17	141	13	29
30 Sep 17	129	16	28
30 Jun 17	117	9	27
31 Mar 17	109	-3	28
31 Dec 16	109	-2	28
30 Sep 16	92	7	27
30 Jun 16	88	205	25
31 Mar 16	87	235	25
31 Dec 15	72	230	25
30 Sep 15	74	231	24
30 Jun 15	71	33	25
31 Mar 15	63	11	23
31 Dec 14	65	12	23
30 Sep 14	56	7	21
30 Jun 14	54	8	19
31 Mar 14	53	10	19
31 Dec 13	49	9	18

Kaliteli Kazançlar: LGND büyük bir tek seferlik kazanç ile $87.5M, 30th September, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: LGND 'nin mevcut net kar marjları (29.7%) geçen yılın (13.7%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: LGND şirketinin kazançları son 5 yılda yılda 47.7% oranında azaldı.

Büyüme Hızlandırma: LGND 'un son bir yıldaki kazanç büyümesi ( 114.5% ) 5 yıllık ortalamasını (yıllık -47.7% ) aşıyor.

Kazançlar vs. Sektör: LGND geçen yılki kazanç büyümesi ( 114.5% ) Pharmaceuticals sektörünün 54.6% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: LGND 'nin Özsermaye Getirisi ( 5.4% ) düşük olarak değerlendiriliyor.

Ligand Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Ligand Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 07, 2024

Ligand Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: EPS: US$4.86 (vs US$2.56 in 1Q 2023)

Ligand Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 27, 2024

Recent updates

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024

Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Ligand Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 07, 2024

Ligand Pharmaceuticals Incorporated Reaffirms Financial Guidance for the Full Year of 2024

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Ligand Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 06, 2024

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into an agreement to acquire APEIRON Biologics AG for $128 million.

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

Chief Financial Officer notifies of intention to sell stock

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

President & COO recently sold US$1.5m worth of stock

Consensus EPS estimates increase by 199%

Chief Legal Officer & Secretary notifies of intention to sell stock

First quarter 2024 earnings released: EPS: US$4.86 (vs US$2.56 in 1Q 2023)

Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 14, 2024

Ligand Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 07, 2024

Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

CEO & Director exercised options to buy US$1.2m worth of stock.

Chief Financial Officer notifies of intention to sell stock

Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Announces Management Appointments

Ligand Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 27, 2024

U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 28%, revenue upgraded

Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ligand Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

CEO & Director recently bought US$238k worth of stock

Ligand Pharmaceuticals Incorporated Appoints Martine Zimmermann to its Board of Directors

Ligand Pharmaceuticals Incorporated Reaffirms Revenue Guidance for 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) announces an Equity Buyback for $50 million worth of its shares.

Ligand's Collaborator Merck Announces V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

Ligand Pharmaceuticals Incorporated to Report Q2, 2023 Results on Aug 08, 2023

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into a stalking horse asset purchase agreement to acquire Substantially All of the Assets of Novan, Inc. for $15 million.

Consensus EPS estimates increase by 73%

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Independent Chairman recently sold US$343k worth of stock

Independent Chairman notifies of intention to sell stock

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

Ligand Pharmaceuticals Incorporated Raises Earnings Guidance for 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 41%

Full year 2022 earnings released: US$0.31 loss per share (vs US$3.44 profit in FY 2021)

Ligand Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 22, 2023

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Executive Director notifies of intention to sell stock

Executive Director exercised options to buy US$998k worth of stock.

Ligand Pharmaceuticals Incorporated Announces CEO Changes

Price target decreased to US$111

CEO & Executive Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%

Insufficient new directors

Chief Financial Officer recently sold US$128k worth of stock

Price target decreased to US$131

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Year 2022

Insufficient new directors

Ligand Pharmaceuticals Incorporated Appoints Octavio (Tavo) Espinoza as Chief Financial Officer